| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.19 | 1e-06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-06 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.2 | 2e-06 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.19 | 2e-06 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.29 | 2e-06 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.24 | 2e-06 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.16 | 4e-06 |